arrow
M

Makito Miyake

Nara Medical University
H指数:40
被引数:5,841

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluating Risk Factors Associating With Late Recurrence After Low-Dose-Rate Brachytherapy for Prostate Cancer Using Machine Learning

利用机器学习评估低剂量率近距离放射治疗前列腺癌后晚期复发的风险因素

2026-09-290
PRE
FGFR3 Gene Alterations and Protein Expression in Paired TURBT and Radical Cystectomy Archival Specimens of Muscle-Invasive Bladder Cancer

FGFR3基因改变和蛋白质表达在配对TURBT和根治性膀胱切除术存档标本中的肌层浸润性膀胱癌

2026-09-290
OA
Prospective multicenter validation of a Urine-Based multiplex assay for risk stratification of patients presenting with gross hematuria

基于尿液的多重检测方法在评估肉眼血尿患者风险分层中的多中心前瞻性验证

2026-08-170
OAAI
Prognostic Significance of Pretreatment Blood-Based Biomarkers in Penile Cancer: A Multicenter Retrospective Study in Japan

日本多中心回顾性研究中阴茎癌预治前血液生物标志物的预后意义

2026-05-203
OAAI
Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer

根治性膀胱切除术治疗非肌层浸润性膀胱癌的肿瘤学结果综合分析

2026-04-050
OAAI
Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy

对接受晚线恩沃利单抗单药治疗的高级别尿路上皮癌患者进行纵向评估,评估其健康相关生活质量、睡眠质量和味觉。

2025-12-280
PRE
Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guérin (BCG) Therapy in BCG-Naïve or -Unresponsive Non-Muscle-Invasive Bladder Cancer

真实世界中根治性膀胱切除术与经尿道巴氏卡介苗(BCG)疗法在BCG初治或难治性非肌层浸润性膀胱癌患者生存结局的比较

2025-12-011
PRE
Impact of body mass index on the efficacy of immune combination therapy in metastatic renal cell carcinoma: a multicenter study in Japan

体重指数对免疫联合疗法在转移性肾细胞癌中疗效的影响:一项在日本进行的多中心研究

2025-08-200
OAAI
Risk factors for early arteriovenous fistula failure in patients undergoing hemodialysis and comparison of diagnostic prediction models

血液透析患者早期动静脉瘘失败的危险因素及诊断预测模型的比较

2025-08-050
PRE
Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort

顺铂为基础的新辅助化疗的有效性及肌肉浸润性膀胱癌患者中残留的膀胱外疾病的风险因素:来自全国队列研究的见解

2025-07-210
PRE
Clinical relevance of Nectin-4 downregulation and biological changes caused by cytotoxic chemotherapy in bladder cancer

Nectin-4下调的临床意义以及细胞毒性化疗在膀胱癌中引起的生物学变化

2025-06-250
PRE
Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study

非肌层浸润性膀胱癌根治性膀胱切除术期间淋巴结清扫的影响:日本多中心回顾性研究

2025-05-100
PRE
Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy

新辅助周期数及辅助化疗的加入对接受根治性膀胱切除术治疗的肌层浸润性膀胱癌预后的影响

2025-04-290
OAAI
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study
2025-01-090
OAAI
Difference in oncological efficacy between subsequent anti-PD-L1 and anti-PD-1 inhibitors following first-line platinum-based chemotherapy for patients with advanced urothelial carcinoma

在晚期尿路上皮癌患者中,在完成一线铂类化疗后,后续使用抗PD-L1抑制剂与抗PD-1抑制剂在肿瘤学疗效方面的差异。

2024-12-010
PRE